1-3 of 3
Jan Fagerberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Brad Pohlman, Ranjana Advani, MD, Madeleine Duvic, MD, Kenneth B. Hymes, MD, Tanin Intragumtornchai, MD, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, MD, Dina Ben-Yehuda, Marie beylot-Barry, Uwe Hillen, Jan Fagerberg, Francine M Foss
Journal: Blood
Blood (2009) 114 (22): 920.
https://doi.org/10.1182/blood.V114.22.920.920
Published: 2009
Journal Articles

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma

Lotta Hansson, Hodjattallah Rabbani, Jan Fagerberg, Anders Österborg, Håkan Mellstedt
Journal: Blood
Blood (2003) 101 (12): 4930–4936.
https://doi.org/10.1182/blood-2002-04-1250
Published: 2003
Journal Articles

Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex–Restricted, CD8- and CD4-Specific T-Cell Responses

Anders Österborg, Qing Yi, Lotta Henriksson, Jan Fagerberg, Susanne Bergenbrant, Mahmood Jeddi-Tehrani, Ulla Rudén, Ann-Kari Lefvert, Göran Holm, Håkan Mellstedt
Journal: Blood
Blood (1998) 91 (7): 2459–2466.
https://doi.org/10.1182/blood.V91.7.2459
Published: 1998